Given the association of increased COX-mediated PGE2-production in tumours with cancer growth and poor survival rates in patients with cancer, our findings therefore identify the PGE2–EP2/EP4 signalling axis in TILs as molecular target to improve T cell immune therapy in cancer patients with PGE2-producing tumours. Here, PTGER2 is linked to neoplasm.